Please login to the form below

Not currently logged in
Email:
Password:

BMS halts trial of hepatitis C drug on safety issues

At least one person in study thought to have developed congestive heart failure

Bristol-Myers Squibb's aspirations to build a lucrative franchise in hepatitis C virus (HCV) treatment suffered a setback after the company was forced to suspend dosing in a mid-stage trial of a combination therapy.

The phase II study was testing BMS' NS5a inhibitor daclatasvir with nucleotide polymerase (NS5b) inhibitor BMS-986094 (formerly INX-189), which was one of the key assets behind the company's $2.5bn acquisition of Inhibitex earlier this year.

The decision to halt the trial was taken "to protect patient safety based on the emergence of a serious safety issue", said BMS, which added that it is now reviewing data on all the patients in the study to try to determine whether the side effect is linked to the drug or some other factor.

The company is remaining tight-lipped about the nature of the safety issue, but it has been reported that at least one patient in the study developed congestive heart failure.

The announcement - so early after the Inhibitex acquisition closed - is a major blow to BMS as the firm races with a number of other pharma companies to develop an all-oral treatment regimen that could replace current HCV therapies based on injectable interferon alpha.

The company is exploring other drugs in combination with daclatasvir in HCV, including Tibotec's NS3 protease inhibitor TMC435, but the regimen with BMS-986094 was considered a cornerstone of its HCV treatment strategy, according to analysts.

HCV treatment has been transformed in recent years with the introduction of new orally-active agents, namely the protease inhibitor class represented by Johnson & Johnson/Vertex/Mitsubishi Tanabe's Incivek/Incivo (telaprevir) and Merck & Co's Victrelis (boceprevir).

Nucleotide polymerase inhibitors or 'nukes' such as BMS-986094 have been tipped as the next big class in HCV, and if BMS is forced to halt development of its compound it will benefit Gilead Sciences, whose own nuke candidate GS-7977 is a little further ahead in development.

BMS had a partnership in place with GS-7977 when it was owned by Pharmasset - a company acquired by Gilead last year for $11bn - but the latter company is now developing the drug in tandem with its own NS5a inhibitor GS-5885.

3rd August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

A new reality for healthcare
When mobile phones came onto the mass market it would have been difficult to see how they were to develop into the ubiquitous multimedia devices they are now. Their power,...
Digital-green-grey.jpg
Are you getting these benefits from your digital technology?
Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?...
Alzheimer's: the numbers we cannot forget
In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Infographics